Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 336 million.
The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. Vicore Pharma intends to use the issue proceeds to finance the phase III clinical trial in COVID-19 patients anticipated to start in Q2 2021 and expected to be fully recruited by the end of Q4 2021, C21 manufacturing and scale up activities including tech transfer, GMP manufacturing and GMP production of capsules, strengthening the company’s IPF franchise and general corporate purposes.
The share issue is subject to subsequent approval at the extraordinary general meeting to be held on 5 March 2021.
Vinge’s team has consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Linnea Petersson.
